Published in
American Association for the Advancement of Science, Science Signaling, 590(12), 2019
DOI: 10.1126/scisignal.aav7259
Links
Tools
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Journal article published in 2019 by
Devon R. Blake 
,
Angelina V. Vaseva,
Richard G. Hodge ,
McKenzie P. Kline,
Thomas S. K. Gilbert ,
Vikas Tyagi ,
Daowei Huang ,
Gabrielle C. Whiten ,
Jacob E. Larson,
Xiaodong Wang ,
Kenneth H. Pearce ,
Laura E. Herring ,
Lee M. Graves,
Stephen V. Frye ,
Michael J. Emanuele
and other authors.
,
Angelina V. Vaseva,
Richard G. Hodge ,
McKenzie P. Kline,
Thomas S. K. Gilbert ,
Vikas Tyagi ,
Daowei Huang ,
Gabrielle C. Whiten ,
Jacob E. Larson,
Xiaodong Wang ,
Kenneth H. Pearce ,
Laura E. Herring ,
Lee M. Graves,
Stephen V. Frye ,
Michael J. Emanuele
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
CDK9 inhibitors may treat KRAS-mutant cancers by inducing MYC protein degradation.